WO1999062550A1 - Therapie anti-allergique pan-specifique - Google Patents

Therapie anti-allergique pan-specifique Download PDF

Info

Publication number
WO1999062550A1
WO1999062550A1 PCT/US1999/012526 US9912526W WO9962550A1 WO 1999062550 A1 WO1999062550 A1 WO 1999062550A1 US 9912526 W US9912526 W US 9912526W WO 9962550 A1 WO9962550 A1 WO 9962550A1
Authority
WO
WIPO (PCT)
Prior art keywords
ige
fragments
composition
binding
compounds
Prior art date
Application number
PCT/US1999/012526
Other languages
English (en)
Inventor
Michael Caplan
Howard Sosin
Original Assignee
Michael Caplan
Howard Sosin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Caplan, Howard Sosin filed Critical Michael Caplan
Priority to AU43339/99A priority Critical patent/AU4333999A/en
Publication of WO1999062550A1 publication Critical patent/WO1999062550A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Definitions

  • the symptoms of allergy in humans and animals are primarily attributable to the release of histamine and a large variety of other bioactive compounds from mast cells and related cell types.
  • the mast cell contains numerous secretary granules in which these substances are stored at extremely high concentrations. Activation of the mast cell results in the fusion of these granules with the cell surface membrane, leading to the exocytosis of the granule contents and the concomitant induction of allergic symptoms.
  • the plasma membrane of these cells are endowed with receptors for the Fc portion of the IgE (Fc ⁇ RI). This receptor binds circulating IgE with very high affinity and retains it at the mast cell surface for extended periods of time.
  • Activation is accomplished through the binding of an allergen simultaneously to more than one polyvalent molecule of Fc ⁇ RI- bound IgE.
  • This "cross linking" of at least two surface-bound IgE molecules brings Fc ⁇ RI proteins into close association with one another in the plane of the mast cell plasma membrane.
  • Kinases associated with these receptors become activated as a result of this proximity, initiating the second messenger cascade which results in cell degranulation.
  • At least one other class of receptors can bind to the Fc portion of IgE.
  • the low affinity receptor for IgE, Fc ⁇ RII also known as CD23
  • Fc ⁇ RII is expressed on mast cells and related cell types, B cells, and subsets of antigen presenting cells. It has been suggested that occupancy of Fc ⁇ RII negatively regulates IgE synthesis.
  • compositions are administered to block IgE binding to cell surface receptors and ultimately displace native IgE from mast cells and related cell types to prevent the activation of these cells during an allergic response and to reduce native IgE synthesis.
  • the compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc ⁇ RI IgE binding sites, and more preferably, Fc ⁇ RI and Fc ⁇ RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens.
  • the compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the
  • IgE IgE, jointly referred to herein as "IgE fragments" unless otherwise stated.
  • mast cells includes all cells expressing on their surface Fc ⁇ RI, including mast cells, basophils, and related cell types.
  • IgE Fragments which bind to IgE receptors Allergen-induced release of mast cell granule contents can be prevented, or minimized, if the Fc ⁇ RI IgE binding sites in the mast cell plasma membrane are occupied with an analogue of IgE which is unable to bind antigen and thus is incapable of initiating receptor cross-linking.
  • the domain of the IgE protein which binds to its receptor is termed the Fc portion. This component of the IgE molecule does not contain any of the variable regions which contribute to the formation of high affinity antigen binding sites.
  • the resultant polypeptides bind with high affinity to mast cells.
  • IgE Fc fragments can effectively block the binding of antigen-specific polyvalent native IgE to mast cell Fc ⁇ RI. Consequently, Fc fragments of the IgE molecule can prevent activation of mast cells by any antigen.
  • the Fc polypeptide can block the binding of IgE to mast cells or basophils in vitro and can block the Prausnitz-Kustner passive sensitization reaction when injected subcutaneously in human subjects (Kenten, et al. Proc. Nat. Acad. Sci. 81:2955-2959, 1984; Coleman, et al. Eur. J.Immunol.
  • affinities of IgE fragments for Fc ⁇ RI reveal that the highest affinity is observed with the entire Fc region, which stretches from amino acids 226-547.
  • the on and off rate constants and hence the equilibrium binding constant observed with this piece are essentially identical to the same parameters measured for native IgE (Helm, et al. I Biol. Chem. 271: 7494-7500, 1996; Keown, et al. Eur. Biophys J. 25: 471- 476. 1997).
  • Recombinant IgE fragments can be prepared by expression in E. coli (Kenten, et al. Proc. Nat. Acad. Sci. 81 :2955-2959, 1984; Coleman, et al. Eur.
  • IgE and IgE fragments synthesized in E. coli is not glycosylated.
  • Recent evidence indicates that synthesis in mammalian cells of an IgE Fc whose glycosylation sites have been eradicated by site-directed mutagenesis produces a molecule whose affinity for Fc ⁇ RI is similar to that of native IgE (Young, et al. Protein Eng. 8:193-199, 1995). It would appear, therefore, that lack of glycosylation does not disrupt the Fc ⁇ RI-binding domain of IgE Fc and that material prepared either in mammalian cells or in E. coli should manifest similar biological activities.
  • non-glycosylated IgE Fc domain exhibits higher affinity binding to the low affinity Fc ⁇ RII receptor than its fully glycosylated counterpart (Young, et al. Protein Eng. 8:193-199, 1995).
  • Hybridomas 7:42-47, 1996 This site can be altered by site-directed mutagenesis to ensure that the Fc molecule is not a substrate for thrombin- mediated degradation.
  • thrombin cleavage and ASGPR- mediated clearance it should be possible to attain higher levels of circulating IgE fragments for longer periods of time than would be possible with the native molecule.
  • the resultant increase in the serum concentration of IgE fragments will favor the binding of this molecule to the surfaces of patient mast cells and will thus speed the displacement of native IgE required for its therapeutic effects. It is critically important that the IgE fragments described herein not induce any immune reaction in the patients who receive it.
  • a DNA construct could be employed in which the nucleotide sequence encoding the leader peptide and N-terminal 10 amino acids of rat preprolactin are fused to the sequence corresponding to amino acids 226-547 of IgE Fc. Interposed between the leader peptide sequence and the Fc coding sequence is a sequence encoding a His 6 tag followed by a Factor Xa cleavage site.
  • the Fc coding sequence will be inserted immediately 3' to the sequence encoding the Factor Xa cleavage site.
  • the protein encoded by this cDNA construct will be translated in association with the rough endoplasmic reticulum (RER) and will be co- translationally transported across the RER membrane with concomitant cleavage of the leader peptide.
  • the protein will pursue the secretory pathway and can be released constitutively from the cells.
  • Metal ion chromatography can be used to recover the secreted His-tagged protein from the culture media. Cleavage with Factor Xa will generate a protein whose N- terminal amino acid residue corresponds to amino acid 226 of the IgE Fc protein sequence.
  • Cleaved protein will be purified by gel filtration chromatography. A similar approach can be taken for bacterial expression. A methionine start codon will follow the promoter sequence, after which will be inserted the His 6 tag and the Factor Xa cleavage site. Bacterially synthesized protein will be recovered from the inclusion bodies, purified by metal ion chromatography, cleaved by Factor Xa and dimerized through oxidation. Once again, the N-terminal residue will correspond to amino acid
  • Intact dimer will be prepared by gel filtration chromatography.
  • the vectors employed to drive synthesis in mammalian, insect or yeast cells or in bacteria will incorporate promoters designed to maximize exogenous protein expression.
  • the IgE used to prepare the analogs can be human or animal, and will typically be animal if monoclonal antibodies are used as a source. Since the methods for immunizing animals yield antibody which is not of human origin, the antibodies could elicit an adverse effect if administered to humans. This is also true if the antibodies are to be administered to any other species which is different from the species of origin of the antibodies.
  • "humanization” refers to modifying the species-specific region of the antibody to be homologous to the species to be treated. Methods for "humanizing" antibodies, or generating less immunogenic fragments of non-human antibodies, are well known.
  • a humanized antibody is one in which only the antigen-recognized sites, or complementarity- determining hypervariable regions (CDRs) are of non-human origin, whereas all framework regions (FR) of variable domains are products of human genes. These "humanized” antibodies present a less xenografic rejection stimulus when introduced to a human recipient.
  • variable region DNA of a selected animal recombinant anti-idiotypic ScFv is sequenced by the method of Clackson, T., et al, Nature. 352:624-688, 1991.
  • animal CDRs are distinguished from animal framework regions (FR) based on locations of the CDRs in known sequences of animal variable genes. Kabat, H.A., et al, Sequences of Proteins of Immunological Interest. 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).
  • the CDRs and FR are identified, the CDRs are grafted onto human heavy chain variable region framework by the use of synthetic oligonucleotides and polymerase chain reaction (PCR) recombination.
  • PCR polymerase chain reaction
  • Codons for the animal heavy chain CDRs are built in four (each 100 bases long) oligonucleotides. Using PCR, a grafted DNA sequence of 400 bases is formed that encodes for the recombinant animal CDR/human heavy chain FR protection.
  • the immunogenic stimulus presented by the monoclonal antibodies so produced may be further decreased by the use of Pharmacia's (Pharmacia).
  • RPAS Recombinant Phage Antibody System
  • ScFv single-chain Fv fragment
  • the heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which codes for a flexible peptide.
  • This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody.
  • ScFv single-chain Fv fragment
  • the recombinant ScFv includes a considerably lower number of epitopes, and thereby presents a much weaker immunogenic stimulus when injected into humans.
  • Compounds Identified by Combinatorial Chemistry It may be preferable to utilize non-peptide compounds to block binding of IgE to the mast cell receptors.
  • Molecules with a given function can be selected for from a complex mixture of random molecules in what has been referred to as "in vitro genetics" (Szostak, TIBS 19:89, 1992) or combinatorial chemistry.
  • In vitro genetics Szostak, TIBS 19:89, 1992
  • One synthesizes a large pool of molecules bearing random and defined sequences and subjects that complex mixture for example, approximately 10 15 individual sequences in 100 ⁇ g of a 100 nucleotide RNA or DNA, to some selection and enrichment process.
  • Ellington and Szostak (1990) estimated that 1 in 10 10 RNA molecules folded in such a way as to bind a given ligand.
  • DNA molecules with binding behavior have also been isolated (Ellington and Szostak, 1992; Bock et al, 1992). Using methodology well known to those of skill in the art, in combination with various combinatorial libraries, one can isolate and characterize those compounds which bind to or interact with the desired target. The relative binding affinity of these compounds can be compared and optimum compounds identified using competitive binding studies which are well known to those of skill in the art.
  • the mast cell receptor(s), or relevant portions thereof can be bound to a solid support, and interacted with various combinatorial libraries. Those molecules which do not bind these molecules at all are removed immediately by elution with a suitable solvent. Those molecules which bind to inactive portions of the receptor(s) can be removed by competitive binding with an excess of a chimeric peptide with the inactive portions represented by human sequences, or sequences from the desired species, and the active portion represented by the sequence from another species. Those compounds which bind to the receptor(s) will remain bound to the solid support, whereas unbound compounds will be removed from the column. Finally, those compounds still bound to the column can be removed, for example, by competitive binding. Following removal, these compounds can be identified and their relative binding affinity compared as described above. Rational Drug Design
  • Drugs with the ability to mimic the function of the portion of the IgE which binds to the mast cell receptors can be identified using rational drug design.
  • the compounds preferably include the surface active functional groups of the IgE, or substantially similar groups, in the same or substantially similar orientation, so that the compounds possess the same or similar biological activity.
  • the surface active functional groups in the IgE possess a certain orientation when they are in their active conformations, in part due to their secondary or tertiary structure.
  • Rational drug design involves both the identification and chemical modification of suitable compounds which mimic the function of the parent molecules.
  • peptidomimetics Compounds that mimic the conformation and desirable features of a particular peptide, e.g., an oligopeptide, but that avoid undesirable features, e.g., flexibility (loss of conformation) and metabolic degradation, are known as "peptidomimetics".
  • Peptidomimetics that have physical conformations which mimic the three dimensional structure of amino acids 226-547 of the human IgE protein, in particular, which have surface active groups as present in this portion of the IgE, or peptidomimetics that have physical conformations which mimic the three dimensional structure of amino acids amino acids 226-547 of the human IgE protein can be used to make the pharmaceutical compositions described herein.
  • the physical conformation of the peptidomimetics are determined, in part, by their primary, secondary and tertiary structure.
  • the primary structure of a peptide is defined by the number and precise sequence of amino acids in the IgE.
  • the secondary structure is defined by the extent to which the polypeptide chains possess any helical or other stable structure.
  • the tertiary structure is defined by the tendency for the polypeptides to undergo extensive coiling or folding to produce a complex, somewhat rigid three-dimensional structure.
  • Computer modeling technology allows visualization of the three- dimensional atomic structure of a selected molecule and the rational design of new compounds which will mimic the molecule or which will interact with the molecule.
  • the three-dimensional structure can be determined based on data from x-ray crystallographic analyses and/or NMR imaging of the selected molecule, or from ab initio techniques based solely or in part on the primary structure, as described, for example, in U.S. Patent No. 5,612,895 to Balaji et al.
  • the computer graphics systems enable one to predict how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity.
  • Data bases including constrained metabolically stable non-peptide moieties may be used to search for and to suggest suitable IgE analogs. Searches can be performed using a three dimensional data base for non- peptide (organic) structures (e.g., non-peptide analogs, and/or dipeptide analogs) having three dimensional similarity to the known structure of the active regions of these molecules. See, e.g., the Cambridge Crystal Structure Data Base, Crystallographic Data Center, Lensfield Road, Cambridge, CB2 1EW, England; and Allen, F. H, et al., Acta Crystallogr.. E35: 2331-2339 (1979). Alternatively, three dimensional structures generated by other means such as molecular mechanics can be consulted. See., e.g., Burkert, et al.,
  • Chemically modified analogs of the active portion of the IgE fragment can also be identified using the techniques described above.
  • Peptidomimetics can be modified to increase bioavailability.
  • the compounds are structurally constrained such that the surface active groups are oriented in the active conformation.
  • the compounds can further include chemical modifications that minimize the metabolic degradation of the compounds once they are administered. See, for example, Spatola, A. F. Chemistry and Biochemistry of Amino Acids. Peptides. and Proteins (Weistein, B, Ed.), Vol. 7, pp.
  • bioisostere refers to atoms or groups of atoms which are of similar size to the atom or group of atoms which are to be replaced, wherein the compound containing the replacement atom or group of atoms retains, to a substantial degree, the biological activity of the original, unmodified peptide. See, for example, Nelson, Mautner, and Kuntz, at pp. 227, 271 and 285, respectively, in Burger's Medicinal Chemistry. Part 1, the Basis of Medicinal Chemistry, 4th Edition, M. E. Wolff, ed. (John Wiley & Sons, NY, 1980).
  • Suitable substitutions include modifying one or more of the amide bonds by replacing the amide nitrogen with an oxygen atom, or a sulfur atom, or by replacing H at the amide nitrogen with an alkyl, aryl, aralkyl or alkaryl group, producing an N-substituted amide, or by replacing the amide group with a methylene moiety, optionally substituted with one or two alkyl, aryl, aralkyl or alkaryl groups, which can in turn optionally be substituted with various functional groups, such as halogens, carbonyl groups, amines, nitriles, azides, thiols, hydroxy groups, and carboxylic acid groups.
  • the alkyl groups are preferably C 1-6 straight, branched or cyclic groups.
  • one or more of the amide bonds present in the peptide backbone can be modified, for example, by replacing the amide carbonyl group with a methylene group (optionally substituted as described above), a thiocarbonyl group, a sulfone moiety or a sulfoxide moiety.
  • the peptide can be further modified by introducing alkyl, aryl, aralkyl or alkaryl substituents, optionally substituted as described above, at one or more of the alpha-carbon atoms, such that the peptide backbone is unchanged, but additional side chain substituents are present in the chemically modified analog.
  • Suitable ⁇ -carbon atom modifications include cyclopropyl groups, ethylidene groups, and primary, secondary or tertiary amines.
  • Chemically modified analogs are typically more resistant to enzymatic cleavage than the native peptides from which they are derived because the modified residues are not typically recognized by the enzymes which degrade naturally occurring proteins. Further, the backbone and side chains of peptides can be modified to provide peptidomimetics with reduced conformational flexibility. Accordingly, the possibility that the peptide will adopt conformation(s) other than the specifically desired conformation(s) can be substantially minimized by appropriate modification.
  • Methods of Chemically Preparing IgE Analogs Once the desired analog (including backbone and side chain modifications, as appropriate) has been identified, chemical synthesis is undertaken, employing standard synthetic techniques. For a given target compound, the skilled artisan can readily identify suitable synthetic approaches for the preparation of the target compound.
  • Proteins can be expressed recombinantly or naturally and cleaved by enzymatic digest, expressed from a sequence encoding just a peptide, or synthesized using standard techniques. It is a routine matter to make appropriate peptides, test for binding, and then utilize the peptides.
  • the peptides are easily prepared by standard techniques. They can also be modified to increase in vivo half-life, by chemical modification of the amino acids or by attachment to a carrier molecule or inert substrate, as discussed above.
  • the peptides can also be conjugated to a carrier protein by standard procedures such as the commercial Imject kit from Pierce Chemicals or expressed as a fusion protein, which may have increased stability. Solid phase synthesis described by J. Merrifield, 1964 J. Am. Chem. Soc. 85,
  • the peptide can also be prepared as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
  • organic acids such as formic acid, acetic acid, propionic acid
  • Peptides containing cyclopropyl amino acids, or amino acids derivatized in a similar fashion can also be used. These peptides retain their original activity but have increased half-lives in vivo. Methods known for modifying amino acids, and their use, are known to those skilled in the art, for example, as described in U.S. Patent No. 4,629,784 to Stammer.
  • compositions Dissociation of IgE from its receptor is extremely slow, exhibiting half-times of days to weeks (Isersky, et al. J. Immunol. 122: 1926-1936, 1979). Consequently, IgE fragments bound to Fc ⁇ RI should produce a stable and long term block of these receptors' capacity to activate mast cells. It must also be noted, however, that in order to be effective, IgE fragments will need to occupy a sufficient number of receptor to block antigen-induced activation of the mast cells. Thus, any pharmaceutical preparation of IgE fragments must be presented in sufficiently high concentration and for a sufficient length of time to displace native IgE from the patient's mast cell population.
  • the compounds described above are preferably administered in a pharmaceutically acceptable vehicle.
  • suitable pharmaceutical vehicles are known to those skilled in the art.
  • the compound will usually be dissolved or suspended in sterile water or saline.
  • Carriers suitable for local release include ointments, salves, lotions, gels, and controlled release formulations, such as liposomes or microspheres
  • Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the bloodstream. Alternatively, the compound can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patent No. 4,906,474, 4,925,673, and 3,625,214.
  • the formulation and method for administration can be used to modulate the specific IgE responses. For example, as described by Vrtala, et al., Int. Arch. Allergy Immunol.
  • an antigen can be administered to an individual through the use of a recombinant expression host, such as an apathogenic Salmonella strain, which can be orally administered.
  • a recombinant expression host such as an apathogenic Salmonella strain
  • C. Direct injection into a muscle of cDNA vector encoding the requisite portion of IgE fragments under the control of a strong muscle-specific promoter. Similar techniques have been employed to express factor Nil in mice (Miller, et al. Gene Therapy 2: 736-742, 1995). To ensure that expression of the exogenous gene could be discontinued in the event that it proved to be deleterious, IgE fragments coding sequence would be flanked by lox sequences. The sequence encoding the CRE recombinase would also be carried by the vector, under the control of a tight inducible promoter.
  • transfected MHC-matched cells expressing and secreting IgE fragments could be infused or implanted. Co-transfection of these cells with the cD ⁇ A encoding the Herpes Simplex Virus thymidine kinase would ensure that they could be killed through the administration of acyclovir, should the need to eliminate them arise (Bonin, et al. Science 276:
  • Inhalation might be expected to deliver extremely high concentrations IgE fragments directly to this important population of nasal and respiratory mast cells.
  • Inhibition of allergen- induced degranulation of nasal and pulmonary mast cells might be expected to dramatically ameliorate symptoms such as allergic rhintis and bronchiolar constriction.
  • the local inactivation of pulmonary and nasal mast cells might be sufficient to bring about significant symptomatic relief.
  • pharmaceutically acceptable carriers will typically by saline, phosphate buffered saline, or water, if the composition is administered by injection.
  • the pharmaceutical preparation of the human IgE fragment, or analogue is administered for the dual purposes of occupying mast cell Fc ⁇ RI receptors so as to prevent allergen-induced degranulation and occupying Fc ⁇ RII receptors to reduce circulating levels of native IgE.
  • This preparation serves as a pan-specific anti-allergy therapy, relieving and preventing allergy symptoms independent of the nature of the allergen. Consequently, patients allergic to multiple substances will be completely treated by this preparation, obviating the need for multiple courses of allergen-specific immunizations.
  • Serum levels of IgE fragments can be measured by quantitative western blot analysis employing an [ I]-conjugated anti-IgE fragments antibody as a probe. Protein in serum samples is separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) followed by electropheretic transfer to nitrocUulose paper. For quantitation purposes, a dilution series of known quantities of IgE is also to be loaded on separate lanes of the same gel. IgE fragments can be distinguished from native IgE by its distinctive molecular weight. Labelled bands are excised and bound radioactivity determined by ⁇ -counting.
  • Fractional levels of IgE fragments bound to Fc ⁇ RI can be determined by quantitative western blotting.
  • Peripheral blood basophils can be isolated from patient serum (Weyer, et al. Clin. and Exp. All. 25 : 935-941 , 1995) and their associated proteins separated by SDS-PAGE followed by electropheretic transfer.
  • the relative quantity of native IgE versus IgE fragments bound to the cells is determined using quantitative western blot analysis employing an [ I]-conjugated anti-IGE fragments antibody as a probe.
  • Native IgE is distinguished from IgE fragments by virtue of their distinct molecular weights. Radioactivity in excised bands can be quantitated by ⁇ -counting and the native IgE/IgE fragments ratio determined.
  • the susceptibility of cells from treated patients to undergo cross- linking dependent granule exocytosis can be determined with peripheral blood basophils, prepared from patient serum (Weyer, et al. Clin. and Exp.
  • Cells can be exposed to a bivalent IgG antibody directed against the Fab portion of IgE.
  • This reagent should not interact with surface-bound IgE fragment. Degranulation is measured by standard techniques (Weyer, et al. 1995). This treatment should not induce basophils from successfully treated patients to degranulate.
  • An IgG antibody directed against the Fc portion of IgE is employed as a positive control to demonstrate that the basophils from treated patients retain the capacity to undergo cross-linking mediated degranulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

l'administration des compositions selon l'invention permet de bloquer la liaison de IgE à des récepteurs et, au bout du compte, de déplacer l'immunoglobuline IgE à l'écart des mastocytes et autres types de cellules connexes afin d'empêcher l'activation de ces cellules pendant une réponse allergique. Ces compostions consistent en un vecteur pharmaceutiquement acceptable pour l'administration locale ou systémique d'une dose d'un composé qui se lie spécifiquement à des sites de liaison IgE du récepteur FcεRI et, idéalement, à des sites de liaisons IgE des récepteurs FcεRI et FcεRII pour empêcher l'activation et la dégranulation de mastocytes par suite d'une exposition à des allergènes. Ces composés peuvent être des molécules IgE ainsi que des fragments et des modifications de ces molécules, tels que des fragments d'IgE, des anticorps d'IgE humanisés ou à chaîne simple, une IgE avec Fab modifié, une IgE ne pouvant faire l'objet d'une liaison réticulée, ou des peptidomimétiques qui se lient sur le même site du récepteur que IgE, conjointement désignés ici, sauf indication contraire, par l'expression 'fragments d'IgE'.
PCT/US1999/012526 1998-06-04 1999-06-04 Therapie anti-allergique pan-specifique WO1999062550A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43339/99A AU4333999A (en) 1998-06-04 1999-06-04 Pan-specific anti-allergy therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/090,375 US6299875B1 (en) 1998-06-04 1998-06-04 Methods to block IGE binding to cell surface receptors of mast cells
US09/090,375 1998-06-04

Publications (1)

Publication Number Publication Date
WO1999062550A1 true WO1999062550A1 (fr) 1999-12-09

Family

ID=22222513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012526 WO1999062550A1 (fr) 1998-06-04 1999-06-04 Therapie anti-allergique pan-specifique

Country Status (3)

Country Link
US (2) US6299875B1 (fr)
AU (1) AU4333999A (fr)
WO (1) WO1999062550A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057087A2 (fr) * 2000-02-02 2001-08-09 Curagen Corporation Nouvelle proteine du type sous-unite beta de recepteur de haute affinite pour l'immunoglobuline epsilon (fceb) et acides nucleiques codant pour celle-ci
WO2002102320A2 (fr) * 2001-06-15 2002-12-27 Tanox, Inc. PROTEINES DE FUSION FCε POUR LE TRAITEMENT DE L'ALLERGIE ET DE L'ASTHME
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP2000481A1 (fr) 2003-02-01 2008-12-10 Tanox, Inc. Anticorps IgE anti-humains haute affinité
EP2115139A1 (fr) * 2007-01-29 2009-11-11 Valtion Teknillinen Tutkimuskeskus Procede de fabrication de nouveaux reactifs a base d'ige

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US7604955B2 (en) * 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
CA2494115A1 (fr) * 2002-08-01 2004-02-12 Northwestern University Mutants de proteines ige et utilisations desdits mutants
PT2805728T (pt) * 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
GB0511771D0 (en) * 2005-06-09 2005-07-20 Novartis Ag Organic compounds
WO2013163176A1 (fr) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticules pour le traitement d'allergies
JP2016516754A (ja) 2013-04-03 2016-06-09 アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 新規のナノ粒子組成物
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499112A1 (fr) * 1991-02-11 1992-08-19 F. Hoffmann-La Roche Ag Anticorps contre un récepteur d'IgE
WO1993004173A1 (fr) * 1991-08-14 1993-03-04 Genentech, Inc. Variantes d'immunoglobulines pour des recepteurs specifiques fc epsilon
WO1995014779A1 (fr) * 1993-11-22 1995-06-01 3I Research Exploitation Limited Fragments d'hig-e ayant subi une mutation et leur derive
WO1996012741A1 (fr) * 1994-10-25 1996-05-02 Glaxo Group Limited Agents de fixation a cd23
WO1997004807A1 (fr) * 1995-07-27 1997-02-13 Genentech, Inc. Procedes de traitement de l'asthme allergique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0545913B1 (fr) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Systèmes de délivrance pour agents pharmacologiques
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499112A1 (fr) * 1991-02-11 1992-08-19 F. Hoffmann-La Roche Ag Anticorps contre un récepteur d'IgE
WO1993004173A1 (fr) * 1991-08-14 1993-03-04 Genentech, Inc. Variantes d'immunoglobulines pour des recepteurs specifiques fc epsilon
WO1995014779A1 (fr) * 1993-11-22 1995-06-01 3I Research Exploitation Limited Fragments d'hig-e ayant subi une mutation et leur derive
WO1996012741A1 (fr) * 1994-10-25 1996-05-02 Glaxo Group Limited Agents de fixation a cd23
WO1997004807A1 (fr) * 1995-07-27 1997-02-13 Genentech, Inc. Procedes de traitement de l'asthme allergique

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US7459158B2 (en) 1998-11-02 2008-12-02 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2001057087A2 (fr) * 2000-02-02 2001-08-09 Curagen Corporation Nouvelle proteine du type sous-unite beta de recepteur de haute affinite pour l'immunoglobuline epsilon (fceb) et acides nucleiques codant pour celle-ci
WO2001057087A3 (fr) * 2000-02-02 2002-02-07 Curagen Corp Nouvelle proteine du type sous-unite beta de recepteur de haute affinite pour l'immunoglobuline epsilon (fceb) et acides nucleiques codant pour celle-ci
WO2002102320A2 (fr) * 2001-06-15 2002-12-27 Tanox, Inc. PROTEINES DE FUSION FCε POUR LE TRAITEMENT DE L'ALLERGIE ET DE L'ASTHME
WO2002102320A3 (fr) * 2001-06-15 2004-08-26 Tanox Inc PROTEINES DE FUSION FCε POUR LE TRAITEMENT DE L'ALLERGIE ET DE L'ASTHME
EP2000481A1 (fr) 2003-02-01 2008-12-10 Tanox, Inc. Anticorps IgE anti-humains haute affinité
US7531169B2 (en) 2003-02-01 2009-05-12 Tanox, Inc. High affinity anti-human IgE antibodies
EP2407485A1 (fr) 2003-02-01 2012-01-18 Tanox, Inc. Anticorps IgE anti-humains haute affinité
US8252284B2 (en) 2003-02-01 2012-08-28 Tanox, Inc. High affinity, anti-human IgE antibodies
US8604171B2 (en) 2003-02-01 2013-12-10 Tanox, Inc. High affinity, anti-human IgE antibodies
US9156908B2 (en) 2003-02-01 2015-10-13 Tanox, Inc. High affinity, anti-human IgE antibodies
EP2115139A1 (fr) * 2007-01-29 2009-11-11 Valtion Teknillinen Tutkimuskeskus Procede de fabrication de nouveaux reactifs a base d'ige
JP2010516747A (ja) * 2007-01-29 2010-05-20 バルティオン テクニリーネン トゥトキムスケスクス ＩｇＥを主成分とする新規試薬の製造方法
EP2115139A4 (fr) * 2007-01-29 2011-03-23 Valtion Teknillinen Procede de fabrication de nouveaux reactifs a base d'ige

Also Published As

Publication number Publication date
US6299875B1 (en) 2001-10-09
US20020076420A1 (en) 2002-06-20
AU4333999A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
AU2018201901B2 (en) Single domain binding molecule
US6299875B1 (en) Methods to block IGE binding to cell surface receptors of mast cells
JP2022095892A (ja) エンジニアリングされたＦｃ構築物に関連する組成物および方法
Shin et al. Transferrin-antibody fusion proteins are effective in brain targeting.
JP5102028B2 (ja) 抗ｃｄ１５４抗体
JP7270105B2 (ja) インスリン類似体およびその使用方法
US8394771B1 (en) Multimeric proteins and methods of making and using same
JP2024045117A (ja) 超長期作用性インスリン－ｆｃ融合タンパク質および使用方法
CN108137708A (zh) 人凝血因子ix融合蛋白及其制备方法与用途
JPH06509944A (ja) 特定Ｆｃεレセプターのための免疫グロブリン変異体
WO1991014438A1 (fr) Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
WO2005067980A2 (fr) Conception d’agents therapeutiques et agents therapeutiques
US20090264359A1 (en) Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
KR20070099584A (ko) 도메인 항체와 컨주게이션되어 혈청 반감기가 증가된ｐｌａｄ 도메인 펩티드
JPH10229887A (ja) 神経ペプチドレセプターｈｆｇａｎ７２の新規なリガンド
Metzger et al. How antibodies work: focus on Fc receptors
WO2023143547A1 (fr) Anticorps anti-cd28 et son utilisation
US7732167B2 (en) Interferon-α/β binding fusion proteins and therapeutic uses thereof
JP2014501528A (ja) 修飾されたヒト腫瘍壊死因子受容体−１ポリペプチドまたはその断片及びその製造方法
AU762711C (en) Identifying peptide ligands of target proteins with target complementary library technology (TCLT)
WO2017123642A1 (fr) Méthodes et utilisations du récepteur associé à l'ostéoclaste (oscar) pour la prévention et le traitement de l'arthrose
TW201019962A (en) Ligands that have binding specificity for DC-SIGN
JPH08507684A (ja) 腫瘍細胞死誘導法
WO2020250940A1 (fr) Agent d'immunosuppression
WO2023143535A1 (fr) Anticorps ciblant il-18bp et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase